VOLUNTARY DISSOLUTION - LIQUIDATION

IMCYSE

Export PDF

Financial year 2024 · closed on 21/05/2024

Net result

-6,2 M €

+81.0% YoY

Revenue

1,5 M €

+43.6% YoY

Equity

-33,4 M €

-23.0% YoY

Workforce

41,9 ETP

-11.0% YoY

Company — Voluntary dissolution - liquidation.

What does IMCYSE do?

IMCYSE is a Public limited company incorporated in 2010. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Liège. It employs on average 41,9 ETP workers (FTE).

Legal situation

● Voluntary dissolution - liquidation

BCE/KBO no. / VAT

BE 0828.385.542

Incorporation

10/08/2010

Legal form

Public limited company

Registered office

Avenue Pré-Aily 14
4031 Liège · WallonieSee on map

Contributed capital

47 352 242,86 €

Latest accounts

21/05/2024

Average workforce

41,9 ETP

Activities (NACE)

72101Research and experimental development on natural sciences and engineering· main 72110Research and experimental development on biotechnology

Joint committees (2)

207
2070

Signals

High revenue

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 14 financial years

	2024		2023		2022		2021		2019		2019		2018		2017		2016		2015		2014		2013		2012		2011
Income statement
Revenue	1,5 M €	+43.6%	1,1 M €	+4.1%	1 M €	+126%	453,5 k €		–		–		–		–		–		–		–		–		–		–
EBITDA	-127,8 k €	+99.3%	-19 M €	-464%	-3,4 M €	+79.1%	-16,1 M €	-167%	-6 M €	-132%	-2,6 M €	-141%	-1,1 M €	+24.6%	-1,4 M €	-94.6%	-736,6 k €	+34.5%	-1,1 M €	-211%	1 M €	+183%	-1,2 M €	-690%	-154,5 k €	-2857%	5,6 k €
Operating result	-5,9 M €	+83.3%	-35,1 M €	-81.8%	-19,3 M €	+24.8%	-25,7 M €	-195%	-8,7 M €	-28.8%	-6,7 M €	-29.9%	-5,2 M €	+3.2%	-5,4 M €	-278%	-1,4 M €	+5.9%	-1,5 M €	-321%	681,1 k €	+155%	-1,2 M €	-670%	-161,2 k €	-2978%	5,6 k €
Net result	-6,2 M €	+81.0%	-32,8 M €	-149%	-13,2 M €	+28.9%	-18,6 M €	-360%	-4 M €	+33.3%	-6,1 M €	+48.5%	-11,8 M €	-220%	-3,7 M €	-446%	-672,8 k €	+48.5%	-1,3 M €	-838%	177 k €	+115%	-1,2 M €	-635%	-163,1 k €	-7113%	2,3 k €
Balance sheet
Equity	-33,4 M €	-23.0%	-27,1 M €	-473%	7,3 M €	-63.9%	20,1 M €	+0.8%	20 M €	+26.4%	15,8 M €	+472%	2,8 M €	-45.3%	5,1 M €	-39.1%	8,3 M €	+93.1%	4,3 M €	+60.8%	2,7 M €	+140%	1,1 M €	+869%	115,1 k €	-58.6%	278,2 k €
Total assets	4,8 M €	+44.8%	3,3 M €	-86.2%	24 M €	-35.8%	37,3 M €	+41.6%	26,4 M €	-2.7%	27,1 M €	+61.4%	16,8 M €	+10.9%	15,1 M €	+5.5%	14,3 M €	+137%	6,1 M €	+39.0%	4,4 M €	+94.5%	2,2 M €	+336%	514 k €	+15.4%	445,4 k €
Cash	2,8 M €	+144%	1,2 M €	-36.3%	1,8 M €	-90.0%	18,1 M €	+88.3%	9,6 M €	+44.3%	6,7 M €	+2101%	302,5 k €	-51.4%	622,1 k €	-75.1%	2,5 M €	+1135%	202,3 k €	-74.8%	802,2 k €	-29.7%	1,1 M €	+733%	137 k €	+1562173%	8,8 €
Debts	36,3 M €	+35.5%	26,8 M €	+89.8%	14,1 M €	+3.9%	13,6 M €	+113%	6,4 M €	-43.4%	11,3 M €	+3.0%	11 M €	+89.3%	5,8 M €	+45.6%	4 M €	+348%	887,4 k €	+19.8%	741 k €	+76.4%	419,9 k €	+201%	139,6 k €	+168%	52,1 k €
Other
Workforce	41,9 ETP	-11.0%	47,1 ETP	0.0%	47,1 ETP	+30.8%	36,0 ETP	+28.6%	28,0 ETP	+24.4%	22,5 ETP	+0.9%	22,3 ETP	+6.2%	21,0 ETP	+28.8%	16,3 ETP	+31.5%	12,4 ETP	+15.9%	10,7 ETP	+55.1%	6,9 ETP	+7.8%	6,4 ETP	+23.1%	5,2 ETP

Governance

Board of directors

Seen on filing of 21/05/2024 · 8 active · 46 ended

Active mandates

Roman AYDOGDU

Liquidator · since 21 mai 2024

Active

BioPharma Management and Consulting

Director · since 18 octobre 2021 · until 21 mai 2024 · 0664.691.906

Represented by Denis BEDORET

Active

Vincent BRICHARD

Director · since 16 février 2021 · until 21 mai 2024

Active

AS Partners

Director · since 13 juin 2019 · until 21 mai 2024 · 0466.690.556

Represented by Stefan YEE

Active

NOSHAQ PARTNERS

Director · since 13 juin 2019 · until 21 mai 2024 · 0808.219.836

Represented by Hugues WALLEMACQ

Active

SPARAXIS

Director · since 13 juin 2019 · until 21 mai 2024 · 0452.116.307

Represented by Christine FRANSSEN

Active

SVR INVEST

Director · since 13 juin 2019 · until 21 mai 2024 · 0479.774.371

Represented by Stijn VANROMPAY

Active

TOMTAA UG

Chairman of the board of directors · since 13 juin 2019 · until 21 mai 2024

Represented by Thomas TAAPKEN

Active

Ended mandates

BioPharma Management and Consulting

Director · since 18 octobre 2021 · until 10 juin 2024 · 0664.691.906

Represented by Denis Bedoret

Ended

BioPharma Management and Consulting

Director · since 18 octobre 2021 · until 21 mai 2024 · 0664.691.906

Represented by Denis BEDORET

Ended

Vincent BRICHARD

Director · since 16 février 2021 · until 06 décembre 2024

Ended

Vincent Brichard

Director · since 08 janvier 2021 · until 06 décembre 2024

Ended

At this address

Other companies at this address

Company	CBE no.
Signatur Biosciences● Active	1019.094.272

Annual accounts

Full financial information

	2024	2023	2022	2021	2020	2019
Type of account	Full model	Full model	Full model	Full model	Full model	Abridged model
Start of the financial year	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020	01/07/2019
Closing of the financial year	21/05/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020	31/12/2019
Length of the financial year	5 months	12 months	12 months	12 months	12 months	6 months
Filing date	13/08/2024	31/07/2024	06/07/2023	14/07/2022	08/07/2021	26/06/2020
General meeting	30/07/2024	30/07/2024	12/06/2023	30/06/2022	10/06/2021	10/06/2020
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

15 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Full model	21/05/2024	30/07/2024	13/08/2024	French	PDF
Full model	31/12/2023	30/07/2024	31/07/2024	French	PDF
Full model	31/12/2022	12/06/2023	06/07/2023	French	PDF
Full model	31/12/2021	30/06/2022	14/07/2022	French	PDF
Full model	31/12/2020	10/06/2021	08/07/2021	French	PDF
Abridged model	31/12/2019	10/06/2020	26/06/2020	French	PDF
Abridged model	30/06/2019	22/11/2019	20/12/2019	French	PDF
Abridged model	30/06/2018	07/12/2018	19/12/2018	French	PDF
Abridged model	30/06/2017	01/12/2017	14/12/2017	French	PDF
Abridged model	30/06/2016	12/12/2016	03/01/2017	French	PDF
Abridged model	30/06/2015	04/12/2015	29/12/2015	French	PDF
Abridged model	30/06/2014	05/12/2014	09/01/2015	French	PDF
Abridged model	30/06/2013	06/12/2013	27/02/2014	French	PDF
Abridged model	30/06/2012	28/12/2012	22/02/2013	French	PDF
Abridged model	30/06/2011	23/12/2011	27/01/2012	French	PDF

Estimate

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 21/05/2024 · 8 active · 46 ended

Active mandates

Roman AYDOGDU

Liquidator · since 21 mai 2024

Active

BioPharma Management and Consulting

Director · since 18 octobre 2021 · until 21 mai 2024 · 0664.691.906

Represented by Denis BEDORET

Active

Vincent BRICHARD

Director · since 16 février 2021 · until 21 mai 2024

Active

AS Partners

Director · since 13 juin 2019 · until 21 mai 2024 · 0466.690.556

Represented by Stefan YEE

Active

NOSHAQ PARTNERS

Director · since 13 juin 2019 · until 21 mai 2024 · 0808.219.836

Represented by Hugues WALLEMACQ

Active

SPARAXIS

Director · since 13 juin 2019 · until 21 mai 2024 · 0452.116.307

Represented by Christine FRANSSEN

Active

SVR INVEST

Director · since 13 juin 2019 · until 21 mai 2024 · 0479.774.371

Represented by Stijn VANROMPAY

Active

TOMTAA UG

Chairman of the board of directors · since 13 juin 2019 · until 21 mai 2024

Represented by Thomas TAAPKEN

Active

Ended mandates

BioPharma Management and Consulting

Director · since 18 octobre 2021 · until 10 juin 2024 · 0664.691.906

Represented by Denis Bedoret

Ended

BioPharma Management and Consulting

Director · since 18 octobre 2021 · until 21 mai 2024 · 0664.691.906

Represented by Denis BEDORET

Ended

Vincent BRICHARD

Director · since 16 février 2021 · until 06 décembre 2024

Ended

Vincent Brichard

Director · since 08 janvier 2021 · until 06 décembre 2024

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Mandates09/09/2024
RUBRIQUE FIN (CESSATION, ANNULATION CESSATION, NULLITE, CONC, REORGANISATION JUDICIAIRE, ETC...) - DEMISSIONS, NOMINATIONS
PDF
Mandates08/08/2024
RUBRIQUE FIN (CESSATION, ANNULATION CESSATION, NULLITE, CONC, REORGANISATION JUDICIAIRE, ETC...) - DEMISSIONS, NOMINATIONS
PDF
Mandates26/04/2022
DEMISSIONS, NOMINATIONS
PDF
Other15/04/2022
DIVERS
PDF
Capital / shares18/11/2021
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS
PDF
Registered office23/06/2021
SIEGE SOCIAL
PDF
Mandates08/04/2021
CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS - STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
PDF
Mandates03/03/2021
CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS - STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

2024
Annual accounts 2024-6,2 M €↑
2023
Annual accounts 2023-32,8 M €↓
2022
Annual accounts 2022-13,2 M €↑
2021
Annual accounts 2021-18,6 M €↓
2019
Annual accounts 2019-4 M €↑
2019
Annual accounts 2019-6,1 M €↑
2018
Annual accounts 2018-11,8 M €↓
2017
Annual accounts 2017-3,7 M €↓
2016
Annual accounts 2016-672,8 k €↑
2015
Annual accounts 2015-1,3 M €↓
2014
Annual accounts 2014177 k €↑
2013
Annual accounts 2013-1,2 M €↓
2012
Annual accounts 2012-163,1 k €↓
2011
Annual accounts 20112,3 k €
10/08/2010
IncorporationPublic limited company

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

IMCYSE

Overview

What does IMCYSE do?

Trend over 14 financial years

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline